ETHIC was a randomised controlled trial of prophylactic enoxaparin versus standard of care (no enoxaparin) in community-based COVID-19 patients
Scale and timeline
1,370 COVID-19 patients in ~10 countries in a community setting required for this study lasting approximately 6 months
Protocol
Participants were randomised to receive either enoxaparin for 3 weeks or the current standard of care
Objective
To assess whether treatment with enoxaparin can reduce the thrombotic burden leading to hospital admissions/poor patient outcomes
THE SPONSOR
The Thrombosis Research Institute is a leader in innovative solutions for the detection and treatment of thrombosis.
Learn more